Conducting a US FDA CVM Animal Drug Safety Study in a GLP Environment

被引：0

|

作者：

Early, R. ^{[1
]}

McPherson, S. ^{[2
]}

Zhou, B. ^{[2
]}

Salminen, W. ^{[3
]}

机构：

[1] RJEarly Consulting, Irvine, CA USA

[2] WuXiAppTec Suzhou Co Ltd, Suzhou, Peoples R China

[3] Camargo Pharmaceut, Cincinnati, OH USA

来源：

INTERNATIONAL JOURNAL OF TOXICOLOGY | 2019年 / 38卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

P203

引用

收藏

页码：46 / 47

页数：2

相关论文

共 50 条

[1] Update on the Office of Drug Safety at the US FDA
Reactions Weekly, 2004, 1015 (1) : 3 - 4
[2] US FDA reports new steps in drug safety
Reactions Weekly, 2007, 1138 (1) : 3 - 3
[3] Report on Drug Safety and the US FDA by the Institute of Medicine
Anthony W. Fox
International Journal of Pharmaceutical Medicine, 2006, 20 (5) : 289 - 291
[4] US FDA enhancing postmarketing drug safety surveillance
Reactions Weekly, 2019, 1780 (1) : 3 - 3
[5] US FDA 2009 drug safety warnings analysed
Reactions Weekly, 2012, 1388 (1) : 4 - 4
[6] The US FDA requires a “new vision of drug safety”
Reactions Weekly, 2006, 1126 (1) : 3 - 3
[7] US FDA Enhancing Postmarketing Drug Safety Surveillance
不详
PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 64 - 64
[8] US FDA report highlights ongoing drug safety initiatives
Reactions Weekly, 2018, 1700 (1) : 2 - 2
[9] US FDA Report Highlights Ongoing Drug Safety Initiatives
不详
PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 298 - 298
[10] US FDA Budget expanded to aid food, drug safety
Dorey, Emma
CHEMISTRY & INDUSTRY, 2009, (10) : 6 - 6

← 1 2 3 4 5 →